NCT03531827 2022-07-12Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide TreatmentNational Institutes of Health Clinical Center (CC)Phase 2 Terminated4 enrolled 12 charts